共 48 条
[1]
Goldstone AH(2001)Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Blood 98 1302-1311
[2]
Burnett AK(2002)Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study Blood 100 3869-3876
[3]
Wheatley K(1997)Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group Blood 90 2952-2961
[4]
Smith AG(2002)Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720 Blood 100 1224-1232
[5]
Hutchinson RM(2001)Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine Blood 98 548-553
[6]
Clark RE(2005)Disease biology rather than age is the most important determinant of survival of patients >or =60 years with acute myeloid leukemia treated with uniform intensive therapy Cancer 103 2082-2090
[7]
Anderson JE(2006)Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Blood 108 3280-3288
[8]
Kopecky KJ(2006)Age and acute myeloid leukemia Blood 107 3481-3485
[9]
Willman CL(undefined)undefined undefined undefined undefined-undefined
[10]
Head D(undefined)undefined undefined undefined undefined-undefined